Literature DB >> 30226509

Synthesis of macrocyclic precursors of the vioprolides.

Eibhlin Butler1, Lucia Florentino, Damien Cornut, Gonzalo Gomez-Campillos, Hao Liu, Andrew C Regan, Eric J Thomas.   

Abstract

The vioprolides are novel depsipeptides that have not been synthesized. However, they have been identified as important targets for synthesis because of their novel biological activities and challenging chemical structures. Following early work on the synthesis of a modified tetrapeptide that contained both the (E)-dehydrobutyrine and thiazoline components of vioprolide D, problems were encountered in taking an (E)-dehydrobutyrine containing intermediate further into the synthesis. A second approach to vioprolides and analogues was therefore investigated in which (E)- and (Z)-dehydrobutyrines were to be introduced by selenoxide elimination very late in the synthesis. A convergent approach to advanced macrocyclic precursors of the vioprolides was then completed using a modified hexapeptide and a dipeptidyl glycerate. In this work, it was necessary to protect the 2-hydroxyl group of the glycerate as its acetate and not as its 2,2,2-trichloroethoxycarbonate. Preliminary studies were carried out on the introduction of the required dehydrobutyrine and thiazoline components into advanced intermediates.

Entities:  

Year:  2018        PMID: 30226509     DOI: 10.1039/c8ob01756e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  2 in total

1.  Impact of Dehydroamino Acids on the Structure and Stability of Incipient 310-Helical Peptides.

Authors:  Daniel Joaquin; Michael A Lee; David W Kastner; Jatinder Singh; Shardon T Morrill; Gracie Damstedt; Steven L Castle
Journal:  J Org Chem       Date:  2019-11-25       Impact factor: 4.354

2.  Total Synthesis of the Cyclic Depsipeptide Vioprolide D via its (Z)-Diastereoisomer.

Authors:  Hanusch A Grab; Volker C Kirsch; Stephan A Sieber; Thorsten Bach
Journal:  Angew Chem Int Ed Engl       Date:  2020-04-20       Impact factor: 15.336

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.